EXPLORE!

Cancer Patients' Response Poor to First COVID-19 mRNA Vaccine Dose

  783 Views

eMediNexus    21 March 2021

Only a quarter of patients with cancer obtained protection against COVID-19 following one dose of the Pfizer/BioNTech COVID-19 vaccine, suggested a prospective study.

The study revealed a considerably low immune efficacy rate of 28% in patients with cancer, including 13% in patients with blood cancers. On the contrary, first-dose seroconversion was noted in 97% of healthy controls, stated investigators in a report posted on the medRxiv preprint server. A second dose, given at day 21, led to adequate immunity in almost all of the cancer patients. The study thus advocated that cancer patients should be prioritized for an early second dose of the vaccine… (Medpage Today) 

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.